Aducanumab ("medicamento para el Alzheimer", sin fundamento) recibe un informe negativo del comité asesor de la @EMA_News A European regulatory panel voted against approval of Biogen Incs (BIIB.O) Alzheimers disease drug. https://www.reuters.com/business/healthcare-pharmaceuticals/biogens-alzheimers-drug-gets-negative-vote-ema-panel-2021-11-17/ 1.1K views19:43
